LONDON – Gut microbiome specialist Enterome Bioscience SA has raised €14.5 million (US$16.5 million) in a series C financing that will fund phase I and phase II development of the lead program in inflammatory bowel diseases (IBD), which is based on small molecules in-licensed earlier this week from Vertex Pharmaceuticals Inc.